CONDENSED CONSOLIDATED STATEMENTS OF LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development expenses	$ 2,933	$ 4,380	$ 14,465	$ 14,994
Selling, general and administrative expenses	14,096	21,283	57,535	47,469
Restructuring (income) expense	(69)	0	3,523	(53)
Total operating expense	16,960	25,663	75,523	62,410
Operating loss	(16,960)	(25,663)	(75,523)	(62,410)
Investment and other income, net	448	489	503	1,531
Interest expense	(3,564)	(1,929)	(9,087)	(5,788)
Gain from release of certain liabilities	0	0	33	166
Loss before income taxes	(20,076)	(27,103)	(84,074)	(66,501)
Income tax provision (benefit)	70	(5,101)	25,940	(11,473)
Net loss	$ (20,146)	$ (22,002)	$ (110,014)	$ (55,028)
Net income (loss) per share – basic (in dollars per share)	$ (0.33)	$ (0.38)	$ (1.85)	$ (0.94)
Net income (loss) per share – diluted (in dollars per share)	$ (0.33)	$ (0.38)	$ (1.85)	$ (0.94)
Weighted average number of shares outstanding - basic (in shares)	60,201	58,585	59,359	58,506
Weighted average number of shares outstanding - diluted (in shares)	60,201	58,585	59,359	58,506